Adjunctive perampanel for partial‐onset seizures

Adjunctive perampanel for partial‐onset seizures Perampanel, a selective, non‐competitive, AMPA receptor antagonist, is approved in >50 countries for adjunctive treatment of partial‐onset seizures (POS), with or without secondarily generalized seizures, and for primary generalized tonic‐clonic seizures in patients with epilepsy aged ≥12 years. In the United States, perampanel was recently approved for monotherapy use for POS in patients with epilepsy aged ≥12 years. Approvals for POS were based on three randomized, double‐blind, placebo‐controlled phase III studies (Studies 304, 305, and 306), in which adjunctive perampanel 4‐12 mg/d reduced the frequency of POS compared with placebo.Study 335 (NCT01618695), a randomized, double‐blind, placebo‐controlled phase III trial, evaluated the efficacy, safety, and tolerability of adjunctive perampanel (4‐12 mg/d) in an Asia‐Pacific population with refractory POS. This study provided an opportunity to explore regional similarities and differences compared with the predominantly Caucasian populations who had participated in Studies 304, 305, and 306. Efficacy and safety outcomes from Study 335 were similar to the previous phase III studies, supporting a consistent profile for perampanel across different populations with POS.In Studies 304 and 305, perampanel 12 mg/d did not appear to offer additional efficacy benefits compared with 8 mg/d, despite the log‐linear relationship between perampanel exposure and efficacy. Therefore, Study 335 explored the perampanel dose‐response relationship http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Scandinavica Wiley

Adjunctive perampanel for partial‐onset seizures

Loading next page...
 
/lp/wiley/adjunctive-perampanel-for-partial-onset-seizures-Y8rTfw2lco
Publisher
Wiley
Copyright
Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
ISSN
0001-6314
eISSN
1600-0404
D.O.I.
10.1111/ane.12905
Publisher site
See Article on Publisher Site

Abstract

Perampanel, a selective, non‐competitive, AMPA receptor antagonist, is approved in >50 countries for adjunctive treatment of partial‐onset seizures (POS), with or without secondarily generalized seizures, and for primary generalized tonic‐clonic seizures in patients with epilepsy aged ≥12 years. In the United States, perampanel was recently approved for monotherapy use for POS in patients with epilepsy aged ≥12 years. Approvals for POS were based on three randomized, double‐blind, placebo‐controlled phase III studies (Studies 304, 305, and 306), in which adjunctive perampanel 4‐12 mg/d reduced the frequency of POS compared with placebo.Study 335 (NCT01618695), a randomized, double‐blind, placebo‐controlled phase III trial, evaluated the efficacy, safety, and tolerability of adjunctive perampanel (4‐12 mg/d) in an Asia‐Pacific population with refractory POS. This study provided an opportunity to explore regional similarities and differences compared with the predominantly Caucasian populations who had participated in Studies 304, 305, and 306. Efficacy and safety outcomes from Study 335 were similar to the previous phase III studies, supporting a consistent profile for perampanel across different populations with POS.In Studies 304 and 305, perampanel 12 mg/d did not appear to offer additional efficacy benefits compared with 8 mg/d, despite the log‐linear relationship between perampanel exposure and efficacy. Therefore, Study 335 explored the perampanel dose‐response relationship

Journal

Acta Neurologica ScandinavicaWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off